Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion by inhibiting the $H^+/K^+$-ATPase enzyme system at the secretory surface of the gastric parietal cell.
## Primary Indications
* Short-term treatment of erosive esophagitis associated with GERD.
* Maintenance of healing of erosive esophagitis.
* Pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
* Prophylaxis of stress-induced upper GI hemorrhage (off-label/institutional protocol dependent).
## Adult Dosing
* **GERD/Erosive Esophagitis:** 40 mg PO or IV once daily for up to 8 weeks.
* **Maintenance of Healing:** 40 mg PO once daily.
* **Pathological Hypersecretory Conditions:** Starting dose 40 mg PO twice daily. Doses up to 240 mg/day have been used clinically; titrate based on acid output.
* **IV Bolus:** 40 mg once daily for up to 7-10 days.
## Pediatric Dosing
* **Erosive Esophagitis (≥ 5 years):**
* 15 kg to < 40 kg: 20 mg PO once daily.
* ≥ 40 kg: 40 mg PO once daily.
* **Note:** Safety/efficacy for children < 5 years or for IV administration in pediatrics is not well-established.
## Dose Adjustments
* **Renal Impairment:** No dosage adjustment necessary.
* **Hepatic Impairment:** No specific dosage adjustment usually required, but use caution; in severe impairment, consider monitoring liver enzymes if therapy is long-term.
* **Elderly:** No dosage adjustment necessary.
## Contraindications
* Hypersensitivity to pantoprazole or any component of the formulation.
* Concomitant use with rilpivirine-containing products.
## Adverse Effects
* **Common:** Headache, diarrhea, nausea, abdominal pain, flatulence.
* **Serious:** *Clostridioides difficile*-associated diarrhea, hypomagnesemia, Vitamin B12 deficiency (with long-term use), acute interstitial nephritis, cutaneous lupus erythematosus, bone fractures (hip, wrist, spine) with high-dose/long-term therapy.
## Key Drug Interactions
* **pH-Dependent Drugs:** Decreased absorption of atazanavir, nelfinavir, erlotinib, and some azole antifungals (e.g., ketoconazole).
* **Methotrexate:** Potential for increased methotrexate levels, particularly in high-dose therapy.
* **Warfarin:** Monitor INR frequently as PPIs may alter metabolism or absorption.
## Monitoring
* Baseline and periodic monitoring of magnesium levels (if long-term therapy or concomitant diuretic use).
* Monitor for symptoms of *C. difficile* (persistent watery diarrhea/fever).
* Assess need for ongoing therapy; deprescribe if no clear evidence-based indication persists (PPI-de-escalation strategies).
## Clinical Pearls
* **Administration:** PO tablets should be swallowed whole; do not split or crush. IV administration must be a slow infusion (15 minutes) or bolus (2 minutes) at a concentration of 0.8 mg/mL.
* **Timing:** Optimal effect for GERD achieved when administered 30–60 minutes before the first major meal of the day.
* **Hospital Use:** Do not use IV pantoprazole beyond 10 days; transition to oral therapy as soon as clinically feasible.
***
*Disclaimer: This information is for educational purposes only. Clinical practice protocols vary by institution. Always verify dosages, contraindications, and drug interactions against the most current FDA-approved prescribing information or institutional clinical guidelines before prescribing or administering medication.*
